Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Escc
Sponsor
Yongtao Han (Other)
Overall Status
Completed
CT.gov ID
NCT05604664
Collaborator
(none)
1,727
1
5.3
324.5
Study Details
Study Description
Brief Summary
The goal of this observational study is to to clarify the focus of lymph node dissection during esophagectomy.. The main question[s] it aims to answer is:
- provide a basis for accurate staging and the relationship between OS and lymph node dissection
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
1727 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic Esophageal Squamous Cell Carcinoma
Actual Study Start Date
:
May 1, 2022
Actual Primary Completion Date
:
Oct 1, 2022
Actual Study Completion Date
:
Oct 10, 2022
Outcome Measures
Primary Outcome Measures
- 5-year survival rate of lymph nodes metastases (%) in patients [2010.1.1-2017.12.30]
Surgical data were retrospectively collected
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Pathologic findings proved ESCC (8th AJCC/UICC stage T1b-4aN0-3M0)
-
Underwent esophagecomy (two-field or three-field LN dissection)
-
The primary tumor was thoracic ESCC
Exclusion Criteria:
-
Located outside the thoracic
-
Patients underwent salvage or R1/R2 esophagecomy
-
The number of resected lymph nodes (RLNs) less than 15
-
With neoadjuvant therapy(NT) or salvage chemoradiotherapy(SCRT)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Sichuan Cancer Hospital and Research Institute | Chengdu | Sichuan | China | 610041 |
Sponsors and Collaborators
- Yongtao Han
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Yongtao Han,
Clinical Professor,
Sichuan Cancer Hospital and Research Institute
ClinicalTrials.gov Identifier:
NCT05604664
Other Study ID Numbers:
- SCCH-TS2203
First Posted:
Nov 3, 2022
Last Update Posted:
Nov 4, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No